Goede, V. and Hallek, M. (2015). Chronic lymphocytic leukemia in elderly patients. Onkologe, 21 (6). S. 486 - 493. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1433-0415

Full text not available from this repository.

Abstract

The majority of patients with chronic lymphocytic leukemia (CLL) are of advanced age and over 70 years old when the disease is diagnosed or requires therapy. Recently, new treatment options have emerged. This article gives a review of current diagnostics and therapy of CLL in elderly patients. A literature search was carried out in PubMed and in congress abstracts. The development and approval of new CD20 antibodies (e.g. ofatumumab, and obinutuzumab) as well as kinase inhibitors (e.g. ibrutinib and idelalisib) have broadened the therapeutic arsenal for elderly patients with CLL. Benefits from these advances have been mainly demonstrated for elderly patients with increased comorbidities and for elderly patients with high risk features (e.g. 17p deletion, p53 mutation and early relapse). For the former group of patients immunochemotherapy and no longer chemotherapy alone is the standard first-line treatment. In the latter group of patients early use of kinase inhibitors which block B-cell receptor signaling and can be taken orally are indicated. Studies are currently being carried out with further agents for targeted therapy (e.g. venetoclax, lenalidomide) as well as with tools for assessing patient fitness in elderly patients with CLL.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Goede, V.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hallek, M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-402957
DOI: 10.1007/s00761-014-2829-5
Journal or Publication Title: Onkologe
Volume: 21
Number: 6
Page Range: S. 486 - 493
Date: 2015
Publisher: SPRINGER HEIDELBERG
Place of Publication: HEIDELBERG
ISSN: 1433-0415
Language: German
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
1ST-LINE TREATMENT; PLUS CHLORAMBUCIL; INITIAL THERAPY; OPEN-LABEL; RITUXIMAB; FLUDARABINE; IBRUTINIB; CYCLOPHOSPHAMIDE; OBINUTUZUMAB; DIAGNOSISMultiple languages
OncologyMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/40295

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item